Today’s Stock Alert: Could Editas Medicine Inc Decline After Today’s Big Increase?

Today's Stock Alert: Could Editas Medicine Inc Decline After Today's Big Increase?

The stock of Editas Medicine Inc (NASDAQ:EDIT) is a huge mover today! About 142,062 shares traded hands. Editas Medicine Inc (NASDAQ:EDIT) has declined 68.52% since April 4, 2016 and is downtrending. It has underperformed by 69.61% the S&P500.
The move comes after 7 months positive chart setup for the $459.42 million company. It was reported on Nov, 4 by Barchart.com. We have $35.78 PT which if reached, will make NASDAQ:EDIT worth $767.23M more.

Analysts await Editas Medicine Inc (NASDAQ:EDIT) to report earnings on November, 8. After $-0.54 actual EPS reported by Editas Medicine Inc for the previous quarter, Wall Street now forecasts 20.37% negative EPS growth.

According to Zacks Investment Research, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.”

More notable recent Editas Medicine Inc (NASDAQ:EDIT) news were published by: Quotes.Wsj.com which released: “News Editas Medicine Inc.EDIT” on January 16, 2015, also Bostonglobe.com with their article: “Editas Medicine raises $94.4 million in year’s first IPO” published on February 02, 2016, Marketwatch.com published: “Plus the latest data from Realtor.com on 21 home markets across the US” on January 06, 2016. More interesting news about Editas Medicine Inc (NASDAQ:EDIT) were released by: Ibtimes.com and their article: “Google-Backed Startup Editas Medicine Becomes First Gene Editing Company To …” published on January 05, 2016 as well as Fortune.com‘s news article titled: “The Hottest IPO of 2016 Is Crashing” with publication date: March 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment